The Annual Congress of the European League Against Rheumatism.

AMPLE trial demonstrates identical safety profiles and efficacy between abatacept and adalimumab in RA Data from AMPLE presented in EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar protection profiles between subcutaneous abatacept and adalimumab sildenafil . AMPLE, the first two-year head-to-mind biologics trial, was made up of 646 biologic-na-ve sufferers with active rheumatoid arthritis similarly randomised to either ABA or ADA, with a stable dose of methotrexate .